Pharmaceutical

China NMPA grants approval for GenFleet’s fulzerasib to treat lung cancer

China has granted approval for GenFleet Therapeutics’ fulzerasib for advanced non-small cell lung cancer (NSCLC).

Aug 27, 2024 - 04:00
China NMPA grants approval for GenFleet’s fulzerasib to treat lung cancer
China has granted approval for GenFleet Therapeutics’ fulzerasib for advanced non-small cell lung cancer (NSCLC).
Read the original article

Tags:

Previous Article

Invenra’s antibody gains US FDA designations for neuroblastoma treatment

Next Article

Janssen’s BALVERSA receives EC approval for metastatic urothelial carcinoma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Novocure’s electric fields device prolongs survival in lung cancer, but doubts remain

STAT+: Novocure’s electric fields device prolongs survi...

Jun 6, 2023

SOF-10 by Chugai Pharmaceutical for Gastric Cancer: Lik...

Oct 25, 2023

In his State of the Union, Biden takes clear aim at ‘Big Pharma’

In his State of the Union, Biden takes clear aim at ‘Bi...

Mar 8, 2024